Use of Therapeutic Drug Monitoring in Amiodarone Treatment: A Systematic Review of Recent Literature

• Published in: Therapeutic drug monitoring Vol. 45; no. 4; p. 487
• Main Authors: Jørgensen, Adam El Mongy, Hermann, Thomas Steffen, Christensen, Hanne Rolighed, Dalhoff, Kim Peder
• Format: Journal Article
• Language: English
• Published: United States 01.08.2023
• Subjects: Amiodarone - adverse effects; Anti-Arrhythmia Agents - therapeutic use; Drug Monitoring; Humans
• ISSN: 1536-3694
• DOI: 10.1097/FTD.0000000000001079

Amiodarone is a class III antiarrhythmic drug used to prevent supraventricular and ventricular tachyarrhythmias. It has substantial toxicity; however, the use of therapeutic drug monitoring (TDM) seems unclear in the absence of a therapeutic range or an association between amiodarone blood concentration and effect. In this review, the authors examined the reported amiodarone blood concentration measurements in the last 10 years and subsequently noted the frequency by which TDM was used to optimize therapy. In March 2022, the Embase and MEDLINE databases were searched for articles published in English in the previous 10 years using the keywords "amiodarone," "therapeutic drug monitoring," or "serum/plasma/blood". This study included 19 of the 478 articles identified. TDM has not been studied in conjunction with regular amiodarone maintenance therapy. One study used TDM during the initial treatment phase but the amiodarone dose was not changed. In 3 other case reports, TDM was used to guide amiodarone treatment through drug-drug interactions, and plasma levels of the active metabolite mono-N-desethyl-amiodarone (MDEA) verified 2 amiodarone toxicities. Because the antiarrhythmic effect of amiodarone is not correlated with blood concentrations and is easily detectable by electrocardiogram, the routine use of TDM in maintenance therapy is controversial, as evidenced by a scarcity of published literature in the recent decade. Furthermore, amiodarone toxicity is evident with normal/low amiodarone or MDEA levels; hence, TDM of amiodarone provides no therapeutic benefit to patients.